Vaxcyte (NASDAQ:PCVX) Receives Buy Rating from Guggenheim

Vaxcyte (NASDAQ:PCVX - Get Free Report)'s stock had its "buy" rating reaffirmed by Guggenheim in a research report issued on Wednesday,Benzinga reports. They currently have a $160.00 price objective on the stock. Guggenheim's price target suggests a potential upside of 119.12% from the stock's previous close.

A number of other equities research analysts have also recently issued reports on the stock. Cantor Fitzgerald reiterated an "overweight" rating on shares of Vaxcyte in a report on Wednesday, November 6th. The Goldman Sachs Group started coverage on shares of Vaxcyte in a report on Friday, December 20th. They issued a "buy" rating and a $135.00 price objective for the company. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $140.00 price objective on shares of Vaxcyte in a report on Wednesday. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $147.50.

Vaxcyte Stock Performance

Shares of NASDAQ PCVX traded down $1.20 during mid-day trading on Wednesday, reaching $73.02. The company had a trading volume of 2,530,601 shares, compared to its average volume of 1,156,456. Vaxcyte has a twelve month low of $58.10 and a twelve month high of $121.06. The stock has a market capitalization of $9.40 billion, a PE ratio of -15.87 and a beta of 0.98. The stock's 50 day moving average is $84.59 and its 200-day moving average is $94.83.

Remove Ads

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share for the quarter, topping analysts' consensus estimates of ($1.16) by $0.14. On average, sell-side analysts anticipate that Vaxcyte will post -4.21 EPS for the current year.

Insider Buying and Selling at Vaxcyte

In other Vaxcyte news, Director Teri Loxam sold 6,250 shares of the company's stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total transaction of $531,937.50. Following the completion of the sale, the director now directly owns 7,175 shares in the company, valued at $610,664.25. This represents a 46.55 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew Guggenhime sold 8,000 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $83.85, for a total transaction of $670,800.00. Following the sale, the chief financial officer now owns 109,491 shares of the company's stock, valued at $9,180,820.35. This trade represents a 6.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 76,616 shares of company stock worth $6,766,481 over the last ninety days. Company insiders own 3.10% of the company's stock.

Institutional Investors Weigh In On Vaxcyte

Hedge funds have recently made changes to their positions in the stock. Natixis Advisors LLC lifted its stake in shares of Vaxcyte by 61.1% in the third quarter. Natixis Advisors LLC now owns 22,697 shares of the company's stock valued at $2,594,000 after buying an additional 8,606 shares during the period. Diversified Trust Co bought a new stake in shares of Vaxcyte in the fourth quarter valued at about $1,433,000. Lisanti Capital Growth LLC lifted its stake in shares of Vaxcyte by 68.1% in the third quarter. Lisanti Capital Growth LLC now owns 32,515 shares of the company's stock valued at $3,715,000 after buying an additional 13,175 shares during the period. WCM Investment Management LLC lifted its stake in shares of Vaxcyte by 52.6% in the third quarter. WCM Investment Management LLC now owns 140,847 shares of the company's stock valued at $15,935,000 after buying an additional 48,543 shares during the period. Finally, Curi RMB Capital LLC bought a new stake in shares of Vaxcyte in the third quarter valued at about $903,000. Institutional investors own 96.78% of the company's stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.